NEW YORK (GenomeWeb) – Qiagen and Chinese in vitro diagnostics firm Maccura Biotechnology announced today that they have formed a joint venture focused on commercializing Qiagen's GeneReader next-generation sequencing system in China and developing gene panels for the Chinese market.

The JV, called Maqgen, will be based in Chengdu, Sichuan Province, and is owned 60 percent by Maccura and 40 percent by Qiagen. Thierry Bernard, senior VP and head of Qiagen's molecular diagnostics business area, said that Qiagen's stake could grow to 49 percent after three years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.